It was this week that Roche Holdings AG RHHBY announced that the Food and Drug Administration has accelerated approval to Tecentriq, an immuno-oncology drug in combination with Celgene Corporation’s CELG Abraxane for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in patients whose tumors express PD-L1, as determined by an … Continue reading “FDA Grants Accelerated Approval for Roche Holdings Tecentriq Drug for Breast Cancer”
